UW-Madison researchers have developed a novel photoreceptor specific promoter-enhancer construct that they call “IMPG2 PE1”, which is based on two distinct regulatory sequences of the human Interp...
Learn More

A UW-Madison researcher has engineered Lactobacillus reuteri (L. reuteri VPL1014) to express a recombinant gene from the chromosome or plasmid. The gene product can be rodent-, monkey-, or human-deriv...
Learn More

UW-Madison researchers have developed a mouse model (PPCD1-Delta 40) for Posterior Polymorphous Corneal Dystrophy (PPCD).They have also developed second mouse model (see P250382US01 below).
Learn More

UW-Madison researchers have developed a mouse model (PPCD1) for Posterior Polymorphous Corneal Dystrophy (PPCD). They have also developed second mouse model (see P250382US02 below).
Learn More

A UW-Madison researcher has engineered Lactobacillus reuteri (L. Reuteri VPL1014) to encode a native antirepressor protein whose expression is placed under the control of an inducible promoter along w...
Learn More

UW-Madison researchers have developed an AI-based method for designing humanized CAR sequences. Using this method, they developed two novel humanized CD19 sequences that can be used for production of ...
Learn More

UW-Madison researchers have developed a method for stopping seizures in patients suffering from acquired epilepsy. The treatment strategy utilizes Tofacitinib, a JAK/STAT inhibitor currently prescribe...
Learn More

A UW-Madison researcher has developed an oral combination therapy for treating fibrolamellar carcinoma (FLC) that utilizes a CDK7 inhibitor and a CDK9 inhibitor. The researcher created a cancer cell l...
Learn More

UW-Madison researchers in collaboration with researchers at the Oak Ridge National Laboratory have developed chelated antimony (Sb) that can be used for targeted Auger radiotherapy. While 119Sb has be...
Learn More

UW-Madison researchers have developed improved methods for optimizing the characteristics of salivary gland-derived mesenchymal stromal cells (MSCs) for therapeutic administration.The inventors have d...
Learn More

UW-Madison researchers and collaborators have developed a suite of four camelid antibodies that specifically bind to fentanyl and carfentanil, a major metabolite of fentanyl. One binds specifically to...
Learn More

UW-Madison researchers have developed a non-viral method of developing CAR NK cells. The inventors tested many parameters along established processes for genetically modifying immune cells without vir...
Learn More

Schistosomiasis is an often-neglected tropical disease caused by blood flukes (helminths). The World Health Organization estimates that over 250 million people require preventive treatment for schisto...
Learn More

UW-Madison researchers have developed a workflow for identifying microbial strains that are effective in treating CDI. Using this workflow, they found that the ability for a microbiome (existing or tr...
Learn More

UW-Madison researchers have developed a focused library of CARM1 protein degraders. These degraders used a known binding molecule of CARM1 with an optimized linker attached to a Von Hippel–Lindau (V...
Learn More

UW-Madsion researchers have developed a method for reducing adiposity and promoting glucose homeostasis through consumption of tripropionin, a triglyceride containing three propionate fatty acids tail...
Learn More

UW-Madison researchers have developed a new CAR T cell technology to be used in combination with targeted radionuclide treatment for treating sold tumors. The patient is dosed with low dose targeted r...
Learn More

UW-Madison researchers in collaboration with a researcher at Clemson University have developed a chemical scaffold that potently inhibits whole Naegleria fowleri parasites in culture. They have prepar...
Learn More

UW-Madison researchers have developed a multi-functional antibiotic nanoparticle that incorporates hemoglobin and the clinically approved antifungal agent naftifine in the core which is coated with re...
Learn More

UW-Madison researchers have developed a novel camelid antibody against the cancer target cMET. As cMET is overexpressed on many tumors, this antibody may be useful for imaging tumors and/or delivering...
Learn More

UW-Madison researchers have developed a novel protocol for generating nearly pure retinal progenitors (PAX6/VSX2 positive cells) without contamination by forebrain cells. Retinas develops from precurs...
Learn More

UW-Madison and UC-San Francisco researchers have developed a treatment for macular degeneration that uses low doses of the clinically approved molecule, zoledronic acid, which is used to treat bone di...
Learn More

UW-Madison researchers have developed a method for increasing butyrate production in the gut. The method includes delivering a microbial community that include certain bacteria, yeasts, and other micr...
Learn More

UW-Madison inventors have developed a new PACE-based platform for rapid discovery of bioactive cyclic peptide protein aggregation inhibitors. By linking cyclic peptide activity to phage reproduction, ...
Learn More

UW-Madison researchers have developed a protein degrader that shuttles targeted extracellular protein into the lysosome using a cyclic peptide that binds to a cellular receptor attached to a binding m...
Learn More